Latest & greatest articles for etanercept

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on etanercept or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on etanercept and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for etanercept

102. Etanercept for rheumatoid arthritis

Etanercept for rheumatoid arthritis Etanercept for rheumatoid arthritis Etanercept for rheumatoid arthritis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Etanercept for rheumatoid arthritis. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Etanercept, a biologic tumor necrosis factor (TNF) antagonist, is a recombinant human TNF receptor

Health Technology Assessment (HTA) Database.2006

103. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2006; 10(31): 1-258 Authors' objectives

Health Technology Assessment (HTA) Database.2006

104. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis

Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Alcaraz A, Bardach A, Ferrante D, Garcia Marti S, Glujovsky D, Lopez A, Regueiro A, Colantonio L. Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No.79. 2006 Authors' objectives The aim of this report was to assess the use of etanercept, infliximab and adalimumab

Health Technology Assessment (HTA) Database.2006

105. Etanercept and infliximab for the treatment of adults with psoriatic arthritis

Etanercept and infliximab for the treatment of adults with psoriatic arthritis Etanercept and infliximab for the treatment of adults with psoriatic arthritis Etanercept and infliximab for the treatment of adults with psoriatic arthritis National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Health and Clinical Excellence. Etanercept and infliximab for the treatment of adults with psoriatic arthritis. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 102. 2006 Authors' objectives The aim of this review is to provide guidance on the use of etanercept and infliximab for the treatment of adults with psoriatic arthritis. Authors' conclusions 1 Guidance 1.1 Etanercept, within its licensed indications, is recommended for the treatment of adults

Health Technology Assessment (HTA) Database.2006

106. Etanercept and efalizumab for the treatment of adults with psoriasis

Etanercept and efalizumab for the treatment of adults with psoriasis Etanercept and efalizumab for the treatment of adults with psoriasis Etanercept and efalizumab for the treatment of adults with psoriasis National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence (...) . Etanercept and efalizumab for the treatment of adults with psoriasis. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 103. 2006 Authors' objectives The aim of this review is to provide guidance on the use of etanercept and efalizumab for the treatment of adults with psoriasis. Authors' conclusions 1 Guidance 1.1 Etanercept, within its licensed indications, administered at a dose not exceeding 25 mg twice weekly is recommended for the treatment of adults

Health Technology Assessment (HTA) Database.2006

107. [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]

[Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation] Az etanercept helye a juvenilis idiopathias arthritis terapiajaban; szisztematikus irodalmi attekintes es gazdasagi elemzes [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation] Az etanercept helye a juvenilis idiopathias arthritis terapiajaban; szisztematikus irodalmi attekintes es gazdasagi elemzes [Etanercept in patients with juvenile (...) idiopathic arthritis: systematic review and economic evaluation] Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L. Az etanercept helye a juvenilis idiopathias

Health Technology Assessment (HTA) Database.2006

108. Etanercept for ankylosing spondylitis

Etanercept for ankylosing spondylitis Etanercept for ankylosing spondylitis Etanercept for ankylosing spondylitis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Etanercept for ankylosing spondylitis. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives

Etanercept consists of two molecules of the human p75 tumor necrosis factor-alpha (TNF (...) -#) receptor joined to the Fc portion of the human immunoglobulin G1 (IgG1). It binds soluble TNF-# with high specificity and affinity, preventing it from binding to the cell surface receptors (TNF-# receptors) on keratinocytes, thereby inhibiting its proinflammatory effects. Etanercept is prescribed=either alone or in combination with conventional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and nonpharmacologic therapy=to reduce the signs and symptoms of ankylosing

Health Technology Assessment (HTA) Database.2006

112. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. 16399150 2006 01 09 2006 01 18 2015 11 19 1474-547X 367 9504 2006 Jan 07 Lancet (London, England) Lancet Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. 29-35 Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment (...) for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition. 618 patients with moderate to severe psoriasis received double-blind treatment with placebo or 50 mg twice-weekly etanercept. The primary efficacy endpoint was a 75% or greater improvement from baseline in psoriasis area and severity index score (PASI 75) at week 12. Secondary and other endpoints included the functional assessment of chronic illness therapy fatigue (FACIT-F) scale, the Hamilton rating

Lancet2006

113. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

Etanercept and efalizumab for the treatment of adults with psoriasis (TA103) Etanercept and efalizumab for the treatment of adults with psoriasis | Guidance and guidelines | NICE Etanercept and efalizumab for the treatment of adults with psoriasis Technology appraisal guidance [TA103] Published date: 26 July 2006 Share Guidance on etanercept (Enbrel) for treating severe psoriasis in adults. The recommendations also apply to etanercept biosimilar products that have a marketing authorisation (...) , because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy. As a result the 'British national formulary' has been updated to say that efalizumab should not be prescribed for patients who are not already taking it. Treatment for patients who are taking efalizumab should be reviewed. Therefore, NICE has withdrawn its guidance on the use of efalizumab for the treatment of adults with psoriasis. Guidance on the use of etanercept for the treatment of adults

National Institute for Health and Clinical Excellence - Technology Appraisals2006

115. Etanercept plus standard therapy for Wegener's granulomatosis.

Etanercept plus standard therapy for Wegener's granulomatosis. 15673801 2005 01 27 2005 02 02 2015 11 19 1533-4406 352 4 2005 Jan 27 The New England journal of medicine N. Engl. J. Med. Etanercept plus standard therapy for Wegener's granulomatosis. 351-61 The majority of patients with Wegener's granulomatosis have disease flares after conventional medications are tapered. There is no consistently safe, effective treatment for the maintenance of remission. We conducted a randomized, placebo (...) -controlled trial at eight centers to evaluate etanercept for the maintenance of remission in 180 patients with Wegener's granulomatosis. The primary outcome was sustained remission, defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis of 0 for at least six months (scores can range from 0 to 67, with higher scores indicating more active disease). In addition to etanercept or placebo, patients received standard therapy (glucocorticoids plus cyclophosphamide or methotrexate). After

NEJM2005

116. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Brennan A, Bansback N, Reynolds A, Conway P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of etanercept (Enbrel), a genetically engineered protein dimmer, as a biological therapy for rheumatoid arthritis (RA) in adults who have failed to respond to at least two disease-modifying antirheumatic drugs (DMARDs). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised

NHS Economic Evaluation Database.2004

117. Etanercept for the treatment of ankylosing spondylitis

Etanercept for the treatment of ankylosing spondylitis Etanercept for the treatment of ankylosing spondylitis Etanercept for the treatment of ankylosing spondylitis Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office for Health Technology Assessment (...) . Etanercept for the treatment of ankylosing spondylitis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of etanercept (trade name Enbrel, marketed by Amgen Canada Inc.) to reduce signs and symptoms in patients with active ankylosing spondylitis. Authors' conclusions A growing amount of literature explores new technologies that are aimed at altering tumour necrosis factor (TNF) alpha activity

Health Technology Assessment (HTA) Database.2004

118. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. 15001324 2004 03 05 2004 04 14 2016 11 24 1474-547X 363 9410 2004 Feb 28 Lancet (London, England) Lancet Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. 675-81 Etanercept (...) and methotrexate are effective in the treatment of rheumatoid arthritis but no data exist on concurrent initiation or use of the combination compared with either drug alone. We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis. In a double-blind, randomised, clinical efficacy, safety, and radiographic study, 686 patients with active rheumatoid arthritis were randomly allocated to treatment with etanercept 25 mg (subcutaneously

Lancet2004

119. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab (...) when added to methotrexate in patients with active rheumatoid arthritis Hochberg M C, Tracy J K, Hawkins-Holt M, Flores R H CRD summary This review compared adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. The authors concluded that the three agents have similar efficacy when combined with methotrexate. Overall, the methods of analysis may mean that the trials were not powered to detect any true treatment effect differences. Head-to-head

DARE.2003

120. Etanercept as monotherapy in patients with psoriasis.

Etanercept as monotherapy in patients with psoriasis. 14627786 2003 11 20 2003 11 25 2015 11 19 1533-4406 349 21 2003 Nov 20 The New England journal of medicine N. Engl. J. Med. Etanercept as monotherapy in patients with psoriasis. 2014-22 Inflammatory cytokines such as tumor necrosis factor (TNF) have been implicated in the pathogenesis of psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis. In this 24-week, double-blind study (...) , 672 patients underwent randomization and 652 either received placebo or received etanercept subcutaneously at a low dose (25 mg once weekly), a medium dose (25 mg twice weekly), or a high dose (50 mg twice weekly). After 12 weeks, patients in the placebo group began twice-weekly treatment with 25 mg of etanercept. The primary measure of clinical response was the psoriasis area-and-severity index. At week 12, there was an improvement from base line of 75 percent or more in the psoriasis area

NEJM2003